Salute e Benessere

Resolution Therapeutics to present EMERALD study design at the British…

Professor Jonathan Fallowfield, Chair of Translational Liver Research and Principal Investigator at the University of Edinburgh, Honorary Consultant Hepatologist at the Royal Infirmary of Edinburgh, will present a poster detailing the study design for the Phase I/II EMERALD study of RTX001, a novel autologous engineered macrophage cell therapy. The study is a multicentre, single-arm, first-in-human, open-label study designed to evaluate the safety and efficacy of RTX001 in patients who have had…
PR Newswire
07/10/2025

Optimum Strategic Communications to Host 17th Annual Healthcare Investor…

Returning to this year's event – by popular demand – is Optimum's 'Investor speed dating' morning, which brings together exciting early-stage companies and leading life sciences investors. Returning to this year's event – by popular demand – is Optimum's'Investor speed dating'morning, which brings together exciting early-stage companies and leading life sciences investors. Mary Clark, CEO of Optimum Strategic Communications, commented: "Despite the tough market conditions we have...
PR Newswire
07/10/2025

Blue Earth Therapeutics Presents Modelling Data Supporting Early Dose…

The model assessed three dosing scenarios, all with dosing at six-weekly intervals: The model assessed three dosing scenarios, all with dosing at six-weekly intervals: The model extrapolated the reductions in tumour-absorbed radiation doses across each of cycles 4-8 using data available from cycles 1-3 and predicted the cumulative tumour absorbed radiation dose for each dosing scenario. The results showed that the front-loaded regimens both increase tumour-absorbed radiation dose; by 15%...
PR Newswire
07/10/2025

UAE Residents embrace proactive, tech-driven, and sustainable healthcare…

Proactive Choices and Digital Health Adoption Proactive Choices and Digital Health Adoption UAE residents are emerging as one of the region's most health-conscious and future-ready populations. A notable 92% of respondents place high importance on taking control of their health and well-being, reflecting a clear shift toward personal accountability. Growing confidence and optimism in digitalisation and artificial intelligence (AI) The study reveals that 77% of residents are...
PR Newswire
07/10/2025

Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the…

Poster presentation:Title:Circularization of Single-Stranded DNA Donor Template Unleashes the Power of Non-Viral Gene Delivery for Long-Term HSCs editing Presenter : Julien Valton, Ph.D., Vice President Gene Therapy at Cellectis Date/Time:Wednesday, October 8, 2025 from 2:00 p.m. to 3:30 p.m. CET Posternumber: P0439Over the past decade, non-viral DNA template delivery has been used with engineered nucleases to target single-stranded DNA sequences in hematopoietic stem...
Nasdaq GlobeNewswire
07/10/2025

Beactica conducts first advisory meeting with the Swedish Medical Products…

About BEA-17 About BEA-17 BEA-17 is a first-in-class small molecule targeted degrader of lysine demethylase 1 (LSD1) and its co-factor CoREST. In syngeneic animal models of cancer, the compound has shown promising potentiation of immune-modulating treatments in several cancer forms, including anti-PD1 checkpoint inhibitors in colon cancer (CT26) and standard of care (temozolomide and radiation) in glioblastoma (GL261). Pharmacokinetic studies of BEA-17 show good blood-brain-barrier...
PR Newswire
07/10/2025

Kadisco General Hospital and MindHYVE.ai™ Sign Strategic MoU to Transform…

Three Pillars of Collaboration Three Pillars of Collaboration Under the MoU, Kadisco and MindHYVE.ai™ will jointly explore pilot programs across three key tracks: Ethiopiafaces one of the lowest doctor-to-patient ratios inAfrica, with fewer than 1.5 physicians per 10,000 people, making access to quality care a critical challenge. Kadisco General Hospital already manages more than 50,000 patient visits and 15,000 emergency cases annually, and through its partnership with MindHYVE...
PR Newswire
07/10/2025

Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.

Alzheimer's disease is a progressive, relentless disease with amyloid beta (Aβ) and tau as hallmarks that is caused by a continuous underlying neurotoxic process that begins before amyloid plaque accumulation and continues after removal.[1],[2],[3] The data show that amyloid-beta protofibrils and tau tangles play roles in the neurodegeneration process,[4],[5],[6] and Leqembi is the only approved treatment that fights Alzheimer's disease in two ways – targeting both amyloid plaque and…
PR Newswire
07/10/2025

UEG Week 2025: Microplastics found to change gut microbiome in first…

The study used stool samples from five healthy volunteers to grow ex vivo gut microbiome cultures. These cultures were then exposed to five common microplastic types – polystyrene, polypropylene, low-density polyethylene, poly(methyl methacrylate) and polyethylene terephthalate – at concentrations reflecting estimated human exposure, as well as higher doses to investigate potential dose-dependent effects. The study used stool samples from five healthy volunteers to grow ex vivo gut microbiome…
PR Newswire
07/10/2025

Lupus Nephritis Market to Advance at a CAGR of 8.5% During the Forecast Period…

Lupus Nephritis Market Summary Lupus Nephritis Market Summary Discover the new lupus nephritis treatment @Lupus Nephritis Treatment Market Key Factors Driving the Growth of the Lupus Nephritis Market Rising Prevalence of Systemic Lupus Erythematosus and Lupus Nephritis The increasing incidence of SLE, particularly in regions likethe United StatesandSouthern Europe, is contributing to a higher number of lupus nephritis cases. In the US, the lupus nephritis...
PR Newswire
06/10/2025

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its…

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that, pursuant to the Company’s At-The-Market program established on September 5, 2025 (the “ATM Program”), it has agreed to issue and sell new ordinary shares (the “Ordinary Shares”) in the form of American...
Nasdaq GlobeNewswire
06/10/2025

Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb)…

New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an injection tracking tool and moreLEQEMBI IQLIK, approved by the U.S. FDA in August 2025, is the first and only anti-amyloid treatment to offer an at-home injection after initial treatment of 18 monthsTOKYO and CAMBRIDGE, Mass., Oct.06, 2025(GLOBE NEWSWIRE) -- Eisai Co., Ltd...
Nasdaq GlobeNewswire
06/10/2025

Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR…

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR FORM AN OFFER FOR SALE OF, OR THE SOLICITATION OF AN OFFER TO BUY, THE SECURITIES REFERRED TO HEREIN IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, SOUTH AFRICA, JAPAN OR ANY OTHER...
Nasdaq GlobeNewswire
06/10/2025

EssilorLuxottica: Third-Quarter 2025 Revenue Conference Call Invitation

Third-Quarter 2025 Revenue Conference Call Invitation Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our Third-Quarter 2025 Revenue Conference Call on: Thursday, October 16, 2025, at 6:30 pm CEST Dial-in telephone access:If you wish to dial into the conference call, please pre-register at the following link to receive the personal credentials (Dial-in numbers, Conference ID and User ID): https://grid...
Nasdaq GlobeNewswire
06/10/2025

Pharming Group provides update on previously announced G&A expense reduction…

Leiden, the Netherlands, October 6, 2025:Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restructuring is aligned with our previously announced plan to reduce general and administrative (G&A) expenses to optimize capital allocation across the organization. The restructuring includes a redesign of Pharming’s organizational structure and a 20%...
Nasdaq GlobeNewswire
06/10/2025

Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon…

New debt facility extends repayment from Q1 2026 to Q4 2030, lowers interest rate and provides access to additional capital for future business developmentCompany adjusts 2025 financial guidance and provides key business updates Saint-Herblain (France), October 6, 2025– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has entered into a debt facility for up to $500 million in non-dilutive financing with funds managed by Pharmakon...
Nasdaq GlobeNewswire
06/10/2025

By 2035, Advanced Wound Care Market Will Surpass USD 20.6 Billion at 7.7% CAGR…

Key Regional Markets Leading Growth: Key Regional Markets Leading Growth: The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.vantagemarketresearch.com/advanced-wound-care-market-1849/request-sample Free Sample Includes: Technological & Industry Momentum: Why This Matters for Executives & Investors? The Advanced Wound Care (AWC) market is rapidly evolving into a multi-billion-dollar growth driver...
PR Newswire
06/10/2025

NCCN Guidelines Navigator for Breast Cancer Genetic Testing and Treatment Debuts…

"The NCCN Guidelines Navigator enables health care providers to quickly find and understand the best available evidence-based options for treating each individual person," said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "The intuitive flow in the NCCN Guidelines Navigator supports easier treatment decision-making based on the latest evidence and expert-consensus. We are pleased to be able to honor Breast Cancer Awareness Month by making some of our most widely used…
PR Newswire
06/10/2025

Clario and the University of Oxford's NeuroMetrology Lab Advance Parkinson's…

Findings from Professor Antoniades' team demonstrate the high potential of movement analysis in PD research and pave the way for predictive and preventive healthcare. In a recent study, a 3-minute in-office assessment predicted fall risk for Parkinson's patients with 84–92% accuracy up to two years in advance and 78% accuracy up to five years in advance. These predictive capabilities may change how the disease is managed and provide greater opportunity to evaluate therapeutic efficacy in…
PR Newswire
06/10/2025

Halia Therapeutics Strengthens Global Genomics Leadership with Appointment of…

"We are thrilled to welcome Paul to Halia. His proven track record in large-scale genomics initiatives—from the UK's 100,000 Genomes Project to the Emirati Genome Programme—makes him an exceptional addition to our leadership team," said David Bearss, Ph.D., CEO of Halia Therapeutics. "His expertise in translating genomic insights into healthcare solutions directly aligns with our mission to develop transformative medicines based on resilience biology." "We are thrilled…
PR Newswire
06/10/2025

Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic…

- Preclinical data for VCN-12, the next candidate from Theriva’s VCN-X discovery program, highlight a novel mechanism of action with the potential to significantly improve antitumor effects -- Pre-ESGCT meeting monograph includes preclinical data demonstrating the feasibility of VCN-01 intracranial administration for the potential treatment of brain tumors - ROCKVILLE, Md., Oct.06, 2025(GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a...
Nasdaq GlobeNewswire
06/10/2025

PBC Biomed Appoints Mark McMahan as Chief Commercial Officer

In his new role, McMahan will oversee global commercialization strategies for PBC Biomed’s proprietary technologies, including OsStic® bioadhesive, ARC, and VAPS. He will also lead commercial planning for client products, such as the ReFeel™ nerve repair solution, supporting the company’s expanding portfolio of innovative medical technologies.Paul Burke, Managing Partner at PBC Biomed, commented:“This announcement reflects PBC Biomed’s commitment to advancing our global presence and...
Nasdaq GlobeNewswire
06/10/2025

Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership…

Exclusive collaboration and license agreement for the development and global commercialisation of Arbor’s clinical-stage gene editing programme, ABO-101 for primary hyperoxaluria type 1 (PH1)Multitarget research collaboration and option agreement for Arbor’s innovative gene editing technologies for the development of additional rare liver disease targetsArbor eligible to receive up to $115M in upfront and near-term payments, along with $2B in potential development, regulatory and...
Nasdaq GlobeNewswire
06/10/2025

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair®…

LONDON, UK and REYKJAVIK, ICELAND (OCTOBER 6, 2025)— Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application...
Nasdaq GlobeNewswire
06/10/2025
Altri  Comunicati